View Older Stories View More Recent Stories

Feb 3, 2022 09:00AM AMGEN AND PLEXIUM ANNOUNCE MULTI-YEAR, DRUG DISCOVERY COLLABORATION TO IDENTIFY NOVEL TARGETED PROTEIN DEGRADATION THERAPIES
Jan 20, 2022 05:52AM Amgen's (AMGN) LUMAKRAS Approved in Japan for Treatment of KRAS G12C-mutated Advanced Non-small Cell Lung Cancer
Jan 20, 2022 04:30AM LUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
Jan 13, 2022 07:05AM Amgen (AMGN) Announces Tezspire Now Available In The United States For The Treatment Of Severe Asthma
Jan 13, 2022 07:00AM TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA
Jan 11, 2022 09:01AM Amgen (AMGN), Arrakis Therapeutics Announce Multi-target Collaboration To Identify Novel Rna Degrader Small Molecule Therapeutics
Jan 11, 2022 09:00AM AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS
Jan 10, 2022 04:00PM AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE THAT KARMA BIOTECHNOLOGIES WILL RECEIVE THE SECOND AMGEN GOLDEN TICKET
Jan 10, 2022 05:41AM Amgen (AMGN) Granted EU Approval for LUMYKRAS to Treat KRAS G12C Mutation of Advanced Non-Small Cell Lung Cancer
Jan 10, 2022 12:00AM EUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
Jan 6, 2022 04:00PM AMGEN TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Jan 6, 2022 09:01AM Amgen (AMGN) and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement
Jan 6, 2022 09:00AM Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement
Jan 6, 2022 09:00AM AMGEN AND GENERATE BIOMEDICINES ANNOUNCE MULTI-TARGET, MULTI-MODALITY RESEARCH COLLABORATION AGREEMENT
Dec 23, 2021 04:00PM AMGEN TO PRESENT AT THE GOLDMAN SACHS 14TH ANNUAL HEALTHCARE CEOS UNSCRIPTED CONFERENCE
Dec 20, 2021 04:26PM Amgen (AMGN) Announces FDA Approves Otezla For The Treatment Of Adult Patients With Plaque Psoriasis, Regardless Of Severity Level
Dec 20, 2021 04:25PM FDA APPROVES OTEZLA® (APREMILAST) FOR THE TREATMENT OF ADULT PATIENTS WITH PLAQUE PSORIASIS, REGARDLESS OF SEVERITY LEVEL
Dec 17, 2021 04:31PM Amgen (AMGN) Announces FDA Approval of TEZSPIRE for Severe Asthma
Dec 17, 2021 04:30PM FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA
Dec 6, 2021 04:00PM Amgen Announces New Data Being Presented At ASH 2021
Dec 3, 2021 04:00PM Amgen Announces 10% Increase In 2022 First Quarter Dividend
Dec 1, 2021 04:00PM Amgen (AMGN) Reports Positive Top-Line Results From Otezla Phase 3 DISCREET Study
Dec 1, 2021 04:00PM Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
Dec 1, 2021 01:28PM FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Re
Nov 29, 2021 04:00PM Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year
Nov 24, 2021 04:05PM Amgen To Present At The 2021 Evercore ISI Healthcare Conference
Nov 24, 2021 04:00PM Amgen To Present At The 2021 Piper Sandler Healthcare Conference
Nov 17, 2021 09:00AM Amgen Awards The Bath Institute of Rheumatic Diseases $25,000 Through UPLIFT Innovation Challenge
Nov 12, 2021 07:30AM Amgen (AMGN) Announces LUMYKRAS Receives Positive Opinion From EMA CHMP For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Nov 12, 2021 07:30AM LUMYKRAS® (sotorasib) Receives Positive Opinion From EMA CHMP For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Nov 10, 2021 04:00PM Amgen To Present At The 2021 Annual Cowen IO Summit
Nov 8, 2021 04:09PM First And Only Randomized, Double-blind, Head-to-head Study Comparing Aimovig® (erenumab-aooe), An Anti-CGRP Pathway Therapy, To Topiramate Published In Cephalalgia
Nov 5, 2021 04:00PM Amgen (AMGN) Begins Construction On New Biomanufacturing Plant In Central Ohio
Nov 5, 2021 04:00PM Amgen Begins Construction On New Biomanufacturing Plant In Central Ohio
Nov 2, 2021 04:01PM Amgen Reports Third Quarter 2021 Financial Results
Oct 28, 2021 04:00PM Amgen Announces Webcast Of 2021 Third Quarter Financial Results
Oct 26, 2021 04:00PM Fortune and Great Place to Work® Name Amgen One of the World's Best Workplaces™ in 2021
Oct 21, 2021 04:00PM Amgen Announces 2021 Fourth Quarter Dividend
Oct 19, 2021 09:17AM Amgen Successfully Completes Acquisition Of Teneobio, Inc.
Oct 7, 2021 09:01AM Amgen (AMGN) Announces New LUMAKRAS Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021
Oct 7, 2021 09:00AM Amgen Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021
Oct 7, 2021 06:37AM Amgen (AMGN), Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases
Oct 7, 2021 06:30AM Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases
Oct 4, 2021 05:54AM Amgen (AMGN) and Kyowa Kirin Announces Positive Phase 2 Data from Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis
Oct 2, 2021 06:00AM Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress
Oct 2, 2021 05:00AM Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083/AMG 451 in Adult Patients with Moderate-to-Severe Atopic Dermatitis at EADV Congress
Sep 29, 2021 05:00PM Amgen To Webcast Investor Call At EADV 2021
Sep 27, 2021 05:49AM Amgen's (AMGN) Repatha Approved by FDA in Pediatric Patients Aged 10 and Older With Heterozygous Familial Hypercholesterolemia
Sep 24, 2021 08:09PM FDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia
Sep 22, 2021 04:00PM Amgen To Present At The 2021 Cantor Global Healthcare Conference
View More Recent Stories View Older Stories